Download PDF
Gesundheitswesen 2002; 64(3): 145-152
DOI: 10.1055/s-2002-22313
Originalarbeiten
© Georg Thieme Verlag Stuttgart · New York

Biologische Marker in der Epidemiologie: Begriffe, Anwendungen, Perspektiven (Teil II)

Biological Markers in Epidemiology: Concepts, applications, Perspectives (Part II)W. Hoffmann, U. Latza, W. Ahrens, K. H. Greiser, A. Kroke, A. Nieters, M. B. Schulze, M. Steiner, C. Terschüren, M. Wjst
  • 1Die Autoren stehen für die gemeinsame Arbeitsgruppe „Epidemiologische Methoden” der Deutschen Arbeitsgemeinschaft Epidemiologie (DAE), der Deutschen Gesellschaft für Sozialmedizin und Prävention (DGSMP) und der Deutschen Gesellschaft für Medizinische Statistik, Biometrie und Epidemiologie (GMDS)
Further Information

Publication History

Publication Date:
18 March 2002 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Im ersten Teil dieses Hintergrundpapiers wurden Begriffe im Kontext der Anwendung von biologischen Markern in epidemiologischen Studien definiert und deren historische Entwicklung am Beispiel der Herz-Kreislauf-Epidemiologie dargestellt. Im Zentrum des zweiten Teils stehen DNA-basierte Biomarker, praktische und methodische Aspekte des Einsatzes von Biomarkern in analytischen epidemiologischen Studien sowie Anforderungen an deren Validierung und Qualitätssicherung. Polymorphismen in der DNA besitzen vermutlich keinen eigenständigen Krankheitswert. Einige können jedoch als Marker zum Nachweis von individueller Sensitivität gegenüber Expositionen und Suszeptibilität für bestimmte Erkrankungen in epidemiologischen Studien eingesetzt werden. Das Human-Genom-Projekt hat zu einem Quantensprung der Möglichkeiten für die Entwicklung von genetischen Markern geführt, deren praktische Bedeutung gegenwärtig noch nicht vollständig ermessen werden kann. Forschungsprogramme zur Untersuchung von Gen-Umwelt-Interaktionen werden jedoch auch zukünftig auf die „traditionellen” epidemiologischen Designs, Methoden und Konzepte angewiesen sein. Berücksichtigung ethischer Prinzipien sowie Anforderungen des Datenschutzes und der „Guten epidemiologischen Praxis” gelten uneingeschränkt auch für die Genetische und Molekulare Epidemiologie.

Abstract

The first part of this paper outlined terms and definitions in the context of the application of biological markers in epidemiological studies. Cardiovascular epidemiology served as an example for their historical development. The second part focusses on DNA-based biomarkers, practical and methodological dimensions of the use of biomarkers in analytic epidemiological studies as well as requirements in respect of validity and quality assurance. Most genetic polymorphisms have no impact on health. However, some can be used as biomarkers for individual sensitvity to exposures and susceptibility for specific diseases. The Human Genome Project has brought about a quantum leap in the development of genetic markers. The practical implications cannot presently be assessed with certainty. However, present and future research programmes of gene-environment interactions depend on „traditional” epidemiological study designs, methods, and concepts. Ethical principles and data protection requirements apply equally to genetic and molecular epidemiology as do the „Guidelines for Good Epidemiological Practice”.

Schlüsselwörter

Biomarker - individuelle Suszeptibilität - individuelle Sensitivität - Molekulare Epidemiologie - SNP - Genetische Polymorphismen - Validität

Keywords

Biomarker - Individual susceptibility - Individual sensitivity - Molecular epidemiology - SNP - Genetic polymorphism - Validity

Literatur

  • 1 Gotoff S P, Amirmokri E, Liebner E J. Ataxia teleangiectasia Neoplasia, untoward response to x-irradiation, and tuberous sklerosis.  American Journal of Diseases of Children. 1967;  114 617-625
    PubMedGoogle Scholar
  • 2 Swift M, Chase C. Cancer in families with xeroderma pigmentosum.  JNCI. 1979;  62 1415-1421
    PubMedGoogle Scholar
  • 3 Parshad R, Sanford K K, Jones G M. Chromatid damage after G2 phase x-irradiation of cells from cancer-prone individuals implicates deficiency in DNA repair.  Proceedings of the National Academy of Sciences. 1983;  80 5612-5616
    PubMedGoogle Scholar
  • 4 German J, Crippa L P, Bloom D. Bloom’s syndrome. III. Analysis of the chromosome aberration characteristic of this disorder.  Chromosoma. 1974;  48 361-366
    CrossrefPubMedGoogle Scholar
  • 5 Bigelow S B, Rary J M, Bender M A. G2 chromosomal radiosensitivity in Fanconi’s anemia.  Mutat Res. 1979;  63 189-199
    PubMedGoogle Scholar
  • 6 Wang S M, Nishigori C, Yagi T, Takebe H. Reduced DNA repair in progeria cells and effects of gamma-ray irradiation on UV-induced unscheduled DNA synthesis in normal and progeria cells.  Mutat Res. 1991;  256 59-66
    PubMedGoogle Scholar
  • 7 Weichselbaum R R, Nove J, Little J B. X-Ray Sensitivity of Fifty-three Human Diploid Fibroblast Cell Strains from Patients with Characterized Genetic Disorders.  Cancer Res. 1980;  40 920-925
    PubMedGoogle Scholar
  • 8 Weemaes C MR, Hustinx T WJ, Scheres J MJC, van Munster P JJ, Bakkeren J AJM, Taalman R DFM. A new chromosomal instability disorder: The Nijmegen Breakage Syndrome.  Acta Paediat Scand. 1981;  70 557-564
    PubMedGoogle Scholar
  • 9 Swift M, Reitnauer P J, Morrell D, Chase C L. Breast and other cancers in families with ataxia teleangiectasia.  N Engl J Med. 1987;  316 1289-1294
    CrossrefPubMedGoogle Scholar
  • 10 Djuzenova C S, Schindler D, Stopper H, Hoehn H, Flentje M, Oppitz U. Identification of ataxia telangiectasia heterozygotes, a cancer-prone population, using the single-cell gel electrophoresis (Comet) assay.  Lab Invest. 1999;  79 699-705
    PubMedGoogle Scholar
  • 11 Swift M, Morrell D, Cromartie E, Chamberlin A R, Skolnick M H, Bishop D T. The Incidence and Gene Frequency of Ataxia-Telangiectasia in the United States.  Am J Hum Genet. 1986;  39 573-583
    PubMedGoogle Scholar
  • 12 Au W W, Oberheitmann B, Heo M Y, Hoffmann W, Oh H Y. Biomarker monitoring for health risk based on sensitivity to environmental mutagens.  Reviews on Environmental Health. 2001;  16 41-64
    PubMedGoogle Scholar
  • 13 Oberheitmann B, Schäfer J, Dally H, Garms A, Frentzel-Beyme R, Hoffmann W. The chromosome-based challenge assay using fluorescence in situ hybridization: a possible test for increased cancer susceptibility.  Mutat Res. 1999;  428 157-164
    PubMedGoogle Scholar
  • 14 Metabolic polymorphisms and susceptibility to cancer. Vineis P, Malats N, Lang M, d’Errico A, Caporaso N, Cuzick J, Bofetta P IARC Scientific Publication No. 148 Lyon; World Health Organisation 1999
    Google Scholar
  • 15 Nakachi K, Imai K, Hayashi S -I, Kawajiri K. Polymorphisms of the CYP1A1 and Glutathione S-Transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population.  Cancer Res. 1993;  53 2994-2999
    PubMedGoogle Scholar
  • 16 Yu M C, Skipper P L, Taghizadeh K, Tannenbaum S R, Chan K K, Henderson B E, Ross R K. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California.  JNCI. 1994;  86 712-716
    PubMedGoogle Scholar
  • 17 Brockmoller J, Kerb R, Drakoulis N, Staffeldt B, Roots I. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study.  Cancer Res. 1994;  54 4103-4111
    PubMedGoogle Scholar
  • 18 Ketterer B, Harris J M, Talaska G, Meyer D J, Pemble S E, Taylor J B, Lang N P, Kadlubar F F. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer.  Environ Health Perspect. 1992;  98 87-94
    PubMedGoogle Scholar
  • 19 Vineis P. Use of biomarkers in epidemiology. The example of metabolic susceptibility to cancer.  Toxicology Letters. 1995;  77 163-168
    PubMedGoogle Scholar
  • 20 Vineis P, Schulte P A. Scientific and ethical aspects of genetic screening of workers for cancer risk: the case of the N-acetyltransferase phenotype.  J Clin Epidemiol. 1995;  48 189-197
    PubMedGoogle Scholar
  • 21 Heckbert S R, Weiss N S, Hornung S K, Eaton D L, Motulsky A G. Glutathion S-Transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers.  JNCI. 1992;  84 414-422
    PubMedGoogle Scholar
  • 22 Seidegård J, Pero R W, Markowitz M M, Roush G, Miller D G, Beattie E J. Isoenzyme(s) of glutathion transferase (class Mu) as a marker for the susceptibilty to lung cancer: A follow up study.  Carcinogenesis. 1990;  11 33-36
    CrossrefPubMedGoogle Scholar
  • 23 Hirvonen A, Saarikoski S T, Linnainmaa K, Koskinen K, Husgafvel K, Mattson K, Vaino H. Glutathione S-Transferase and N-Acetyltransferase Genotypes and Asbestos-Associated Pulmonary Disorders.  JNCI. 1996;  88 1853-1856
    PubMedGoogle Scholar
  • 24 El-Zein R, Conforti-Froes N, Au W W. Interactions Between Genetic Predisposition and Environmental Toxicants for Developement of Lung Cancer.  Environmental and Molecular Mutagenesis. 1997;  29 1-10
    PubMedGoogle Scholar
  • 25 Hietanen E, Husgafvel-Pursiainen K, Vainio H. Interaction between Dose and Susceptibility to Environmental Cancer: A Short Rewiew.  Environ Health Perspect. 1997;  105 Suppl.4 749-754
    PubMedGoogle Scholar
  • 26 Hirvonen A. Combinations of Susceptible Genotypes and Individual Responses to Toxicants.  Environ Health Perspect. 1997;  105, Suppl.4 755-758
    PubMedGoogle Scholar
  • 27 Hirvonen A. Genetic factors in individual responses to environmental exposures.  J Occup Environ Med. 1995;  37 37-43
    PubMedGoogle Scholar
  • 28 Kempkes M, Golka K, Reich S, Reckwitz T. Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder.  Arch Toxicol. 1996;  71 123-126
    PubMedGoogle Scholar
  • 29 Seidegård J, Ekström G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics.  Environ Health Perspect. 1997;  105,Suppl.4 791-799
    PubMedGoogle Scholar
  • 30 Lang N P. Acetylation as an Indicator of Risk.  Environ Health Perspect. 1997;  105, Suppl.4 763-766
    PubMedGoogle Scholar
  • 31 Soskolne C L. Ethical, social, and legal issues surrounding studies of susceptible populations and individuals.  Environ Health Perspect. 1997;  105, Suppl.4 837-841
    PubMedGoogle Scholar
  • 32 Doerffer K, Unrau P. Cancer Genes and Risk Assessment.  Health Phys. 1998;  74 173-180
    PubMedGoogle Scholar
  • 33 Khoury M J, Little J. Human genome epidemiologic reviews: The beginning of something HuGE.  Am J Epidemiol. 2000;  151 2-3
    PubMedGoogle Scholar
  • 34 Cotton S C, Sharp L, Little J, Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: A HuGE review.  Am J Epidemiol. 2000;  151 7-32
    PubMedGoogle Scholar
  • 35 Ashley-Koch A, Yang Q, Olney R S. Sickle hemoglobin (HbS) allele and sickle cell disease: A HuGE review.  Am J Epidemiol. 2000;  151 839-845
    PubMedGoogle Scholar
  • 36 Brockton N, Little J, Sharp L, Cotton S C. N-acetyltransferase polymorphisms and colorectal cancer: A HuGE review.  Am J Epidemiol. 2000;  151 846-861
    PubMedGoogle Scholar
  • 37 Botto L D, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review.  Am J Epidemiol. 2000;  151 862-877
    CrossrefPubMedGoogle Scholar
  • 38 Dorman J S, Bunker C H. HLA-DQ locus of the human leucocyte antigen complex and type 1 diabetes mellitus: A HuGE review.  Epidemiol Rev. 2000;  22 218-227
    PubMedGoogle Scholar
  • 39 Kelada S N, Shelton E, Kaufmann R B, Khoury M J. Delta-aminolaevulinic acid dehydratase genotype and lead toxicity: A HuGE review.  Am J Epidemiol. 2001;  154 1-13
    PubMedGoogle Scholar
  • 40 Geisler S A, Olshan A F. GSTT1, and risk of squamous cell carcinoma of the head and neck: A mini-HuGE review.  Am J Epidemiol. 2001;  154 95-105
    PubMedGoogle Scholar
  • 41 Boone C W, Kellof G J, Malone W E. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review.  Cancer Res. 1990;  50 2-8
    PubMedGoogle Scholar
  • 42 Vineis P, D’Amore F, Working G roup on the Epidemiology of Hematolymphopoetic Malignancies in Italy. The role of occupational exposure and immunodeficiency in B-cell malignancies.  Epidemiology. 1992;  3 266-270
    PubMedGoogle Scholar
  • 43 Zahm S H, Blair A. Pesticides and Non-Hodgkin’s Lymphoma.  Cancer Res. 1992;  52 5485s-5488s
    PubMedGoogle Scholar
  • 44 Diel F, Schock B, Modi R, Schrimpf D, Mitsche T, Borck H, Diel E. Wirkungen von Pyrethroiden auf menschliche Lymphozyten in vitro.  Umwelt & Gesundheit. 1995;  3 70-75
    PubMedGoogle Scholar
  • 45 Roboz J, Greaves J, Bekesi J G. Polybrominated biphenyls in model and environmentally contaminated human blood: Protein binding and immunotoxicological studies.  Environ Health Perspect. 1985;  60 107-113
    PubMedGoogle Scholar
  • 46 Stehr-Green P A, Naylor P H, Hoffmann R E. Diminished thymosin alpha-1 levels in persons exposed to 2,3,7,8-Tertrachlorodibenzo-p-dioxin.  J Toxicol Environ Health. 1989;  28 285-295
    PubMedGoogle Scholar
  • 47 Kiecolt-Glaser J K, Glaser R. Psychoneuroimmunology and cancer: Fact or fiction?.  Eur J Cancer. 1999;  35 1603-1607
    PubMedGoogle Scholar
  • 48 Wu H, Wang J, Cacioppo J T, Glaser R, Kiecolt-Glaser J K, Malarkey W B. Chronic stress associated with spousal caregiving of patients with Alzheimer's dementia is associated with downregulation of B-lymphocyte GH mRNA.  J Gerontol A Biol Sci Med Sci. 1999;  54 M212-M215
    PubMedGoogle Scholar
  • 49 Kiecolt-Glaser J K. Norman Cousins Memorial Lecture 1998. Stress, personal relationships, and immune fuction: health implications.  Brain Behav Immun. 1999;  13 61-72
    PubMedGoogle Scholar
  • 50 Holden R J, Pakula I S, Mooney P A. An immunological model connecting the pathogenesis of stress, depression an carcinoma.  Medical Hypothesis. 1998;  51 309-314
    PubMedGoogle Scholar
  • 51 Knekt P, Raitasalo R, Heliövaara M, Lehtinen V, Pukkala E, Teppo L, Maatela J, Aromaa A. Elevated lung cancer risk among persons with depressed mood.  Am J Epidemiol. 1996;  144 1096-1103
    PubMedGoogle Scholar
  • 52 Penninx B WJH, Guralnik M P, Ferrucci L, Cerhan J R, Wallace R B, Havlik R J. Chronically Depressed Mood and Cancer Risk in Older Persons.  JNCI. 1998;  90 1888-1893
    CrossrefPubMedGoogle Scholar
  • 53 Lander E S. et al . Initial sequencing and analysis of the human genome.  Nature. 2001;  409 860-921
    CrossrefPubMedGoogle Scholar
  • 54 Venter J C, Adams M D, Myers E W. et al . The sequence of the human genome.  Science. 2001;  291 1304-1351
    CrossrefPubMedGoogle Scholar
  • 55 Marth G, Yeh R, Minton M, Donaldson R, Li Q, Davenport R, Miller R D, Kwok P Y. Single-nucleotid polymorphisms in the public databases: How useful are they?.  Nature Genetics. 2001;  27 371-372
    PubMedGoogle Scholar
  • 56 Wjst M. Checklisten zu Design, Durchführung und Datenanalyse in der molekularen Epidemiologie.  Med Genetik. 2000;  12 416-417
    PubMedGoogle Scholar
  • 57 Schulte P A. A conceptual and historical framework for molecular epidemiology. Schulte PA, Perera F Molecular epidemiology San Diego New York Boston London Sydney Tokyo Toronto; Academic Press 1993: 3-44
    Google Scholar
  • 58 Schulte P A, Perera F P. Transitional studies. Toniolo P, Boffetta P, Shuker DEG, Rothman N, Hulka B, Pearce N Application of Biomarkers in Cancer Epidemiology. IARC Scientific Publications No. 142 Lyon; International Agency for Research on Cancer 1997: 19-29
    Google Scholar
  • 59 Potter J D. Logistics and design issues in the use of biological samples in observational epidemiology. Toniolo P, Boffetta P, Shuker DEG, Rothman N, Hulka B, Pearce N Application of Biomarkers in Cancer Epidemiology. IARC Scientific Publications No. 142 Lyon; International Agency for Research on Cancer 1997: 31-8
    Google Scholar
  • 60 Armstrong B K, White E, Saracci R. Validity and reliability studies. Principles of exposure measurement in epidemiology. Monographs on epidemiology and biostatistics. v. 21 Oxford; Oxford University Press 1994: 78-114
    Google Scholar
  • 61 Vineis P. Sources of variation in biomarkers. Toniolo P, Boffetta P, Shuker D, Rothman N, Hulka B, Pearce N Application of biomarkers in cancer epidemiology. IARC Scientific Publications No. 142 Lyon; International Agency for the Research on Cancer (IARC) 1997: 59-71.
    Google Scholar
  • 62 Altman D G. Practical statistics for medical research. London; Chapman & Hall 1991
    Google Scholar
  • 63 Latza U, Wilhelm D, Seyfarth M, Davis S, McKnight B, Stein H. Soluble cytokine receptor CD30 in atopic disorders: A case-control study.  Clin Exp Allergy. 1999;  29 97-104
    PubMedGoogle Scholar
  • 64 Rose G. Preventive cardiology: What lies ahead ?.  Prev Med. 1990;  19 97-104
    PubMedGoogle Scholar
  • 65 Deutsche A rbeitsgemeinschaft Epidemiologie (DAE). Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP).  Gesundheitswesen. 2000;  62 295-302
    Article in Thieme ConnectPubMedGoogle Scholar

Korrespondenzadresse

PD Dr. med. Wolfgang  Hoffmann, MPHSprecher der AG Methoden

c/o Bremer Institut für Präventionsforschung und Sozialmedizin (BIPS)

Linzer Straße 8-10

28359 Bremen

Email: Hoffmann@BIPS.Uni-Bremen.de